Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: A study from the british society of blood and marrow transplantation registry

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 11, 2011, Pages 1638-1645

  Cook, Gordon ^a   Liakopoulou, Effie ^b   Pearce, Rachel ^c   Cavet, Jim ^b   Morgan, Gareth J ^d   Kirkland, Keiren ^c   Lee, Julia ^c   Davies, Faith E ^d   Hall, Rachel ^e   Rahemtulla, Amin ^f   Russell, Nigel ^g   Marks, David I ^h  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b Christies Hospitals Trust   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Autologous stem cell transplantation; Myeloma; Salvage

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REGISTER; RETROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 80054848892     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.04.005     Document Type: Article

References (34)

1. Schey S. Survival from multiple myeloma in England and Wales up to 2001. Br J Cancer 2008, 99(Suppl 1):S113-S115.
2. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006, 24:929-936.
3. Blade J., Esteve J., Rives S., et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000, 26:845-849.
4. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
5. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
6. Blade J., Rosinol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106:3755-3759.
7. Kastritis E., Zervas K., Symeonidis A., et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009, 23:1152-1157.
8. Rachet B., Mitry E., Shah A., et al. Survival from multiple myeloma in England and Wales up to 2001. Br J Cancer 2008, 99(Suppl 1):S110-S112.
9. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
10. Tricot G., Jagannath S., Vesole D.H., et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995, 16:7-11.
11. Qazilbash M.H., Saliba R., De Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006, 106:1084-1089.
12. Alvares C., Davies F., Horton C., et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006, 91:141-142.
13. Elice F., Raimondi R., Tosetto A., et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006, 81:426-431.
14. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
15. Morris C., Iacobelli S., Brand R., et al. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 2004, 22:1674-1681.
16. Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007, 25:2434-2441.
17. Dingli D., Pacheco J.M., Nowakowski G.S., et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007, 25:4933-4937.
18. Paiva B., Vidriales M.B., Cervero J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
19. Bensinger W.I. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 2009, 23:442-448.
20. van Rhee F. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?. Nat Clin Pract Oncol 2008, 5:70-71.
21. Lenain C., Dumontet C., Gargi T., et al. Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma. Hematol J 2004, 5:403-409.
22. Smith S.M., van Besien K., Carreras J., et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008, 14:904-912.
23. Thomson K.J., Peggs K.S., Blundell E., et al. A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft. Leuk Lymphoma 2007, 48:881-884.
24. Olin R.L., Vogl D.T., Porter D.L., et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009, 43:417-422.
25. Burzynski J.A., Toro J.J., Patel R.C., et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009, 50:1442-1447.
26. Alvares C.L., Davies F.E., Horton C., et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006, 91:141-142.
27. Tricot G., Jagannath S., Vesole D.H., et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995, 16:7-11.
28. Qazilbash M.H., Saliba R., De Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006, 106:1084-1089.
29. Lee C.K., Barlogie B., Zangari M., et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002, 30:873-878.
30. Mark T., Niesvizky R., Coleman M. Novel agents in myeloma: an exciting saga. Cancer 2009, 115:236-242.
31. Laubach J.P., Mahindra A., Mitsiades C.S., et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009, 23:2222-2232.
32. Lonial S., Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009, 145:681-708.
33. Richardson P.G., Weller E., Jagannath S., et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009, 27:5713-5719.
34. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan in elderely untreated patients iwht multiple myeloma: resuslts of a phase I/II study. Blood 2006, 108(7):2165-2172.